Choose an Injection Site The first step in administering Ozempic is selecting the right injection site
The evidence base supporting the therapeutic rationale for using GLP-1/GIP receptor agonists in Type 1 Diabetes (T1D) with overweight or obesity has both strengths and weaknesses
Patients with coexisting diabetes or obesity and Crohn's disease require careful coordination between specialists, as GLP-1 agonists' gastrointestinal side effects overlap significantly with IBD symptoms, potentially complicating disease monitoring and management
Addictive Behavior It is believed that GLP1 receptor agonists may positively influence addictive behavior, such as drug and alcohol use, eating, and smoking, through impacting the reward center in the brain
Healthcare providers can offer guidance on dosing strategies to mitigate side effects while maintaining the efficacy of the medication.
TIPS: The capsules should separate easily by gently squeezing on the larger portion and twisting